Ox40r binding agents
CA 2480694 A1 · Owner: Merck Serono Sa · Inventors: Soto Jara, Claudio; Pena Rossi, Claudia
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention discloses peptides isolated from the extracellular domain of OX40 Ligand (OX40L) capable of binding OX40 Receptor (OX40R) and inhibiting OX40R-OX40L interaction. Such peptides fusion proteins comprising , them, as well as peptides and other molecules designed on their sequences can , be used as OX40R binding agents competing with natural OX40L for blocking OX40R-mediated cell signaling in the prophylaxis and/or treatment of diseases related to activated T cells.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 2, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended April 2, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 2, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.